Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

KB 2796

Known as: KB-2796 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Abstract NMDA receptor antagonists have been demonstrated to be neuroprotective in focal cerebral ischemia and are supposed to… Expand
1998
1998
NMDA receptor antagonists have been demonstrated to be neuroprotective in focal cerebral ischemia and are supposed to prevent… Expand
1993
1993
The effects of KB-2796, 1-[bis(4-fluorophenyl)methyl]-4-(2,3,4- trimethoxybenzyl)piperazine-2HCl, on the low- and high-voltage… Expand
1993
1993
The effects of the novel calcium channel antagonist KB-2796, other calcium channel antagonists, an N-methyl-D-aspartate (NMDA… Expand
1991
1991
Abstract— The effects of KB‐2796, a new diphenylpiperazine analogue, on [3H]nitrendipine ([3H]NTD) binding, KCl‐induced… Expand
1990
1990
The protective effect of KB-2796, a new calcium antagonist possessing a selective vasodilator activity on cerebral vessels in… Expand
1990
1990
The effects of a new calcium entry blocker, KB-2796, on cerebral and peripheral circulation were compared with those of four… Expand
Highly Cited
1989
Highly Cited
1989
Abstract: The effects of a new calcium channel blocker, l‐[bis(4‐fluorophenyl)methyl]‐4‐(2,3,4‐trimethoxybenzyl)‐piperazine… Expand
1988
1988
The effect of KB-2796, a new diphenylpiperazine calcium antagonist, on [3H]nitrendipine ([3H]NTD) binding was investigated in… Expand
1988
1988
Effects of a new Ca2+ antagonist, 1-[bis(4-fluorophenyl) methyl]-4-(2,3,4-trimethoxybenzyl) piperazine dihydrochloride (KB-2796… Expand